Brent Sabatini Sells 7,711 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 7,711 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $9.12, for a total transaction of $70,324.32. Following the transaction, the chief accounting officer owned 61,902 shares in the company, valued at approximately $564,546.24. The trade was a 11.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Brent Sabatini also recently made the following trade(s):

• On Tuesday, February 24th, Brent Sabatini sold 1,430 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.53, for a total transaction of $13,627.90.
• On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total value of $13,626.05.
• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total value of $11,918.70.

Vir Biotechnology Stock Down 3.1%

Vir Biotechnology stock opened at $8.57 on Wednesday. The business has a 50 day moving average price of $8.16 and a two-hundred day moving average price of $6.65. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -2.71 and a beta of 1.65. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. During the same quarter last year, the company earned ($0.76) EPS. The company’s quarterly revenue was up 417.8% on a year-over-year basis. On average, analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Evercore reiterated an “outperform” rating and set a $18.00 price target on shares of Vir Biotechnology in a research note on Tuesday, February 24th. Leerink Partners restated an “outperform” rating and issued a $20.00 price objective on shares of Vir Biotechnology in a research note on Thursday, February 26th. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective for the company in a report on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Finally, Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $20.44.

Institutional Trading of Vir Biotechnology

Large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology during the second quarter valued at $35,000. FNY Investment Advisers LLC acquired a new stake in shares of Vir Biotechnology in the 3rd quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after purchasing an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.